HeartBeam Inc. (NASDAQ: BEAT) announced it will hold a conference call on August 13 at 4:30 p.m. ET to discuss financial results for the second quarter ended June 30, 2026, and provide updates on its strategy to accelerate global adoption of its ambulatory ECG signal platform. The call will feature Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, and Chief Financial Officer Timothy Cruickshank, who will deliver prepared remarks followed by a question-and-answer session.
The announcement comes as HeartBeam continues to advance its proprietary 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to its technology. The platform is designed to enable cable-free, portable ECG collection from three non-coplanar directions, synthesizing signals into a 12-lead ECG for use outside medical facilities.
HeartBeam's technology aims to transform cardiac care by allowing physicians to identify trends and acute conditions remotely, directing patients to appropriate care without requiring a hospital visit. The company's focus on ambulatory monitoring addresses a growing need for accessible cardiac diagnostics, particularly as healthcare systems seek to reduce costs and improve patient outcomes through remote monitoring.
Investors and analysts will be keen to hear updates on commercialization efforts and adoption rates following the FDA clearances. The second-quarter results will provide insight into revenue growth, operational expenses, and cash position. The company's strategy to accelerate global adoption may include partnerships, distribution agreements, or expansion into new markets.
For more details, the full press release is available at https://ibn.fm/sqGLs. The conference call will be accessible via a webcast or dial-in number, with details provided on HeartBeam's investor relations page. The company also maintains a newsroom at https://ibn.fm/BEAT for the latest updates.
HeartBeam's cleared indications for use are detailed on its website at https://www.heartbeam.com/indications. The company's ability to secure regulatory clearances and patents underscores its innovative approach to cardiac monitoring, positioning it as a key player in the digital health space.
